TY - JOUR
T1 - Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
AU - The Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) network
AU - Mahadeo, Kris M.
AU - Khazal, Sajad J.
AU - Abdel-Azim, Hisham
AU - Fitzgerald, Julie C.
AU - Taraseviciute, Agne
AU - Bollard, Catherine M.
AU - Tewari, Priti
AU - Duncan, Christine
AU - Traube, Chani
AU - McCall, David
AU - Steiner, Marie E.
AU - Cheifetz, Ira M.
AU - Lehmann, Leslie E.
AU - Mejia, Rodrigo
AU - Slopis, John M.
AU - Bajwa, Rajinder
AU - Kebriaei, Partow
AU - Martin, Paul L.
AU - Moffet, Jerelyn
AU - McArthur, Jennifer
AU - Petropoulos, Demetrios
AU - O’Hanlon Curry, Joan
AU - Featherston, Sarah
AU - Foglesong, Jessica
AU - Shoberu, Basirat
AU - Gulbis, Alison
AU - Mireles, Maria E.
AU - Hafemeister, Lisa
AU - Nguyen, Cathy
AU - Kapoor, Neena
AU - Rezvani, Katayoun
AU - Neelapu, Sattva S.
AU - Shpall, Elizabeth J.
N1 - Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.
AB - In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19 + acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which can lead to rapid cardiorespiratory and/or neurological deterioration. Multidisciplinary medical vigilance and the requisite health-care infrastructure are imperative to ensuring optimal patient outcomes, especially as these therapies transition from research protocols to standard care. Herein, authors representing the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have collaborated to provide comprehensive consensus guidelines on the care of children receiving CAR T cell therapy.
UR - https://www.scopus.com/pages/publications/85052923365
U2 - 10.1038/s41571-018-0075-2
DO - 10.1038/s41571-018-0075-2
M3 - Review article
C2 - 30082906
AN - SCOPUS:85052923365
SN - 1759-4774
VL - 16
SP - 45
EP - 63
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 1
ER -